[Blocking TrkB-BDNF signal pathway decreases the livability of neuroblastoma cells]

Area of Science:

• Neuro-oncology research focusing on molecular mechanisms of drug resistance.
• Cellular signaling pathways involved in cancer progression and treatment.
• Pharmacological targeting of receptor tyrosine kinases in pediatric malignancies.

Context:

• Neuroblastoma (NB) cells exhibit chemoresistance, often linked to the brain-derived neurotrophic factor (BDNF) and its receptor TrkB.
• This resistance contributes to poor patient prognosis.
• Understanding and overcoming this resistance is crucial for improving NB treatment outcomes.

Purpose:

• To investigate the effect of blocking the TrkB-BDNF signaling pathway on neuroblastoma cell sensitivity to cisplatin (CDDP).
• To evaluate the efficacy of the tyrosine kinase inhibitor K252a in modulating chemoresistance.
• To assess changes in cell viability and apoptosis following pathway inhibition.

Summary:

• Treatment with K252a, an inhibitor of the TrkB-BDNF pathway, significantly increased the sensitivity of SH-SY5Y neuroblastoma cells to cisplatin.
• K252a treatment led to decreased cell viability and increased apoptosis rates in neuroblastoma cells exposed to cisplatin.
• Western blot analysis confirmed that K252a effectively blocked TrkB autophosphorylation, indicating successful pathway inhibition.

Impact:

• The findings suggest that targeting the TrkB-BDNF pathway could be a viable strategy to enhance chemotherapy effectiveness in neuroblastoma.
• This research may pave the way for novel therapeutic approaches to overcome chemoresistance in NB.
• Further studies could explore K252a or similar inhibitors in combination therapies for neuroblastoma treatment.